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Abstract We compared the expression of human ~- and 
~-defensins by various human tissues, mRNA for cc-defensins 
HNP1-3, abundant in bone marrow, was detected in peripheral 
blood leukocytes, spleen and thymus by RT-PCR, which revealed 
cc-defensins HD5 and HD6 only in the small intestine. In 
contrast, the pancreas and kidney expressed high levels of hBD-1 
and lower levels of this [~-defensin were found in many organs by 
RT-PCR (salivary gland > trachea > prostate and placen- 
ta > thymus, testis, small intestine), hBD-1 mRNA was produced 
constitutively by cultured normal human epithelial cells derived 
from the trachea, bronchi, small airways and the mammary 
gland. These largely non-overlapping tissue distributions of 
human a~- and [~-defensins suggest hat hBD-1 may be positioned 
to defend epithelial cells and mucosae from infection, whereas 
expression of HNP1-3 in neutrophils and HD5 and HD6 in 
Paneth cells allows these cc-defensins to participate in systemic 
and small intestinal host defenses, respectively. 
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I. Introduction 
Mammal ian  defensins are 3.5~,.5 kDa antimicrobial  pep- 
tides whose [3-sheet structures are stabilized by three intramol- 
ecular cystine disulfide bonds [1]. Two families, called c~- and 
]3-defensins, exist in mammals  and birds [2-7]. Six c~-defensins 
and one ]3-defensin are known in humans (Fig. 1). a-Defen- 
sins HNP1, -2, -3 and -4 are found in neutrophi ls [1] and HD5 
and HD6 in small intestinal Paneth cells [8-10]. The only 
known human [3-defensin, hBD-1, was isolated from plasma 
and noted to be expressed by the kidney and the female re- 
productive tract [11]. [3-defensins occur in leukocytes of cattle 
[2,3] and fowl [4,5] and in bovine tracheal and lingual epithe- 
lial cells [6,7]. The human hBD-1 gene is on chromosome 
8p23, within 100-150 kb of the gene for HNP1, suggesting 
that e~- and [3-defensins descended from a shared ancestral 
gene [12]. To gain addit ional insights into the respective roles 
of the two defensin families, we compared the expression of c~- 
and [3-defensins in various normal human tissues. 
2. Materials and methods 
serum-free medium (SFM) was changed every other day, and con- 
sisted of a basal medium (Clonetics) supplemented with 0.5 Bg/ml 
hydrocortisone, 0.5 ng/ml recombinant human epidermal growth fac- 
tor, 0.5 Bg/ml epinephrine, 10 Bg/ml transferrin, 5 pg/ml insulin, 0.1 
ng/ml retinoic acid, 6.5 ng/ml triiodothyronine, 50 Bg/ml gentamicin, 
and 50 ng/ml amphotericin B.
Bronchial/tracheal pithelial cells were cultured in SFM with 52 gg/ 
ml bovine pituitary extract. Mammary epithelial cells were grown in 
SFM with 52 Bg/ml bovine pituitary extract and 10 ng/ml of epider- 
mal growth factor, but without epinephrine, transferrin, retinoic acid 
or tri-iodothyronine. Small airway epithelial cells were grown in SFM 
containing 30 gg/ml of bovine pituitary extract and 0.5 mg/ml of fatty 
acid-free bovine serum albumin. The HTB-41 human submaxillary 
epidermoid carcinoma cell line and HTB-81 prostatic arcinoma cell 
lines were obtained from the American Type Culture Collection, 
Rockville, MD. The submaxillary cells were grown in McCoy 5A 
medium (Gibco, Grand Island, NY) and the prostate cells in Eagle's 
Minimal Essential Medium (Gibco), both supplemented with 10% 
heat-inactivated fetal calf serum. 
In some experiments, RNA was harvested from cells cultured for 
4-20 h with one of the following stimuli: 100 ng ml a E. coli 055:B5 
lipopolysaccharide (Sigma), 100 ng ml a phorbol myristate acetate 
(Sigma), 80 ng m1-1 recombinant human interleukin 6 (Gibco, Grand 
Island, NY), 100 U m1-1 recombinant human interferon-,/(Boehrin- 
ger Mannheim, Indianapolis, IN) or 20 ng m1-1 TNF-o~ (Boehringer 
Mannheim) and subjected to RT-PCR as described below. 
2.2. RNA purification and reverse transcriptase (RT-PCR) 
Total RNA was purified from cultured cells and peripheral blood 
leukocytes with the RNeasy Total RNA kit (QIAGEN Inc., Chats- 
worth, CA). Total RNA from thymus, prostate, testis, salivary gland, 
skeletal muscle, placenta, small intestine, kidney, trachea, spleen, bone 
marrow (all human) was also purchased from Clontech (Palo Alto, 
CA). cDNA (20 BI) was synthesized from 1 Bg of each total RNA 
with a Clontech cDNA kit. A 115 dilution of cDNA (10 I.tl) was added 
to a mixture (50 pl final volume) that contained 1~tl of dNTP mix (10 
mM each), 1 ~1 5' and 3' primers (25 laM each), and 2.5 U of cloned 
pfu DNA polymerase (Stratagene, La Jolla, CA), The PCR primers 
and the expected product sizes (Table 1) are based on published se- 
quences [8,9,15]. Primer A-1 (sense) corresponds to nucleotides 110 
136 of the hBD-1 cDNA sequence and Primer A-2 (antisense) is
complementary to the 3' end of hBD-1, immediately before its 
poly(A) tail [11,12]. The human ]3-actin control amplimer set (Clon- 
tech) generated a product of 838 bp. 
PCR was performed as follows with an automated DNA thermal 
cycler for 25, 30, 35 cycles: denaturation, 1 min at 94°C; annealing, 
1 min at 60°C; extension, 2.5 min at 72°C. We used a master eagent 
mix to ensure tube to tube consistency in cDNA synthesis and PCR 
reactions and included a negative control reaction in each experiment. 
Reaction products (10 B1) were visualized after electrophoresis in 1.3% 
agarose gels containing 1 Bg ml-1 ethidium bromide. 
2.1. Cell culture and total RNA purification 
Primary cultures of the following normal human cells were obtained 
from Clonetics Corporation (San Diego, CA): first-passage bronchial/ 
tracheal epithelial cells, second-passage small airway epithelial cells 
and sixth-passage mammary epithelial cells. Cells were passaged twice 
to 80 90% confluence in Coming 75 cm 2 tissue culture flasks. The 
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2.3. Subcloning, DNA sequencing, Northern blots 
PCR products of hBD-1 around 250 bp in size were cloned into 
pCR-Script SK vector (Stratagene, La Jolla, CA). DNA sequencing 
was performed with a kit, according to the manufacturer's instruc- 
tions (US Biochemical Corp., Cleveland, OH). Commercial multiple 
tissue blots of human poly A + RNA were obtained from Clontech 
and represented the following tissues: heart, brain, placenta, lung, 
liver, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, tes- 
tis, ovary, small intestine, colon and peripheral blood leukocytes. The 
membranes were hybridized with a radiolabeled synthetic oligonucleo- 
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tide, 5'-CTTGCAGCACTTGGCCTTCCCTCTGTAACAGGTGCC- 
TTGAATTTTGGTAAAGATCGGGCA-3', complementary to the 
hBD-1 cDNA sequence before the stop codon [11,12]. Fifteen micro- 
grams of total RNA was hybridized to a full-length BD-1 cDNA 
probe labeled by the random oligonucleotide method. The RNA 
bands were separated on 1% agarose formaldehyde g ls and trans- 
ferred to Gene Screen Plus nylon membranes (DuPont, Boston, MA) 
by capillary transfer. 
2.4. Quantitative imaging 
PCR products (30 cycles) of hBD-1 were separated on a 1.3% 
agarose gels, transferred to nylon membranes and hybridized with 
[ct-32p]dCTP labelled hBD-I cDNA. Quantitative analysis was per- 
formed with a Phosphor Imager 445 SI (Molecular Dynamics, Sun- 
nyvale, CA). To compare mRNA expression i different tissues, data 
from each tissue were initially normalized by the formula: relative 
amplified product:(Pti~,o/Pm~)× 100, wherein Pt i  ...... was the amount 
of amplified product obtained from each tissue, and P ..... was an 
amplified product obtained from kidney. The resulting data were 
then renormalized by setting the next highest sample (submaxillary 
gland) to 100%. 
3. Results and discussion 
Although synthesis of hBD-1 by human kidney and female 
productive tract [11,16] and of human c~-defensins HNP1-3 
and HD5 and HD6 by myeloid cells [15] and Paneth cells [8,9] 
respectively has been reported, the expression of these human 
defensins has not been systematically compared, tissue by tis- 
sue. Our Northern blots confirmed abundant production of 
hBD-1 by kidney, but also revealed substantial expression by 
the pancreas (Fig. 2). The production of hBD-I by various 
sites within the female genitourinary tract [16] will be de- 
scribed elsewhere. The prominent expression of hBD-1 in 
the pancreas might be related to protecting pancreatic ductal 
and acinar epithelial cells from retrograde infection via the 
pancreatic duct, or might contribute to the antimicrobial 
properties of pancreatic secretions [17], thereby compensating 
for the low density of c~-defensin producing Paneth cells in the 
duodenum [18]. 
After 25 cycles of RT-PCR, hBD-1 transcripts were evident 
only in the kidney and submaxillary salivary gland. In con- 
trast, HNP1 3 transcripts were prominent after 25 RT-PCR 
cycles in the bone marrow, peripheral blood leukocytes, pleen 
and thymus (Fig. 3). After 30 cycles of PCR, hBD-1 tran- 
scripts were also seen in prostate, testis, placenta, small intes- 
tine and trachea, whereas HNP1-3 transcripts were evident in 
the prostate, submaxillary salivary gland, placenta nd tra- 
chea. 
We found little or no evidence of HNP1 3 production by 
the kidney, which had large amounts of hBD-I mRNA, the 
small intestine (which expressed HD5 and HD6) (Fig. 4) or 
the testis (which was reported to express large amounts of a 
Table 1 
PCR primers used in this study 
..... iY .. IRIpAI 
HNP-2  y -- R IPA  ( 
HNP 3 D Y . . . .  R IPA  ( 
HNP 4 V S . . . . .  RLVF  ( 
HD -5 ARAT y - - -  RTGR ( 
HD 6 TRAFT H . . . .  RR-S  ( 
hBD 1 DHYN VSSGGQ LYSA 
IA ERR TIYQZ LwAF I 
IAGERRY T IYQ RLWAF'  
IAGERRY T IYQ RLWAF,  
RRTELRV N L IG  VSFTY '  
ATRESLS V E IS  RLYRL ,  
YSTEYSY T TVM INHRF 
P IFTK IQ T YR  KAK- -  
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R 
L 
K 
Fig. 1. Amino acid sequences of seven human defensins, hBD-l is a 
[3-defensin, the others are et-defensins. The typical cystine disulfide 
pairing of et-defensins is shown by double lines above and that typi- 
cal of [3-defensins is shown by the lines below the sequences. Gaps 
(-) were introduced to maximize the alignment of e~- and 13-defen- 
sins, and 8 residues that are highly conserved in c~-defensins (6 cys- 
teines and 2 glycines) are boxed. 
cathelin-associated antimicrobial peptide [19,20]). Because all 
tissues contain multiple cellular elements that contribute to 
their total mRNA pool, we purified RNA from normal 
epithelial cells that were derived from the upper (trachea 
and bronchi) and lower airways or from mammary gland, 
and also recovered RNA from human prostate and submax- 
illary gland cell lines. We identified mRNA encoding hBD-1 
in all of those cells by RT-PCR, but not by Northern blotting 
(data not shown). With the phosphor-imaging system, we 
performed a more quantitative evaluation of hBD-1 expres- 
sion by several of the RT-PCR positive/Northern blot-nega- 
tive tissues. Relative to submaxillary gland (100%), their levels 
of hBD-1 expression were: trachea, 76.9%; prostate, 62.7%; 
placenta, 54.5%; thymus, 37.8%; small intestine, 29.4%; and 
testis 24.8%. Considerably ower levels of product were found 
in the bone marrow (9.0%), skeletal muscle (8.9%), spleen 
(6.5%) and peripheral blood leukocytes (5.4%). 
As mRNAs for bovine mucosal epithelial J3-defensins, tra- 
cheal antimicrobial peptide ('TAP') and lingual antimicrobial 
peptide ('LAP') are induced after challenge with bacterial li- 
popolysaccharide, tumor necrosis factor alpha (TNF-c 0, and 
traumatic injury [7,13,14], we decided to examine hBD-1 ex- 
pression for evidence of similar responsivity. To ensure our 
ability to detect increased numbers of hBD-1 transcripts, we 
mixed various proportions of RNA from cultured tracheal/ 
bronchial epithelial cells, which contained relatively high 
hBD-1 transcript numbers, with RNA from cultured small 
airway epithelial cells, which contained relatively low tran- 
script numbers, to a final weight of 1 p.g and performed 
RT-PCR on the mixtures. As we saw the expected relationship 
between the hBD-1 RNA input and the final amount of am- 
plified product, we were confident of our ability to detect 
increased relative levels of hBD-1 had they occurred. 
Primary cultures of normal human tracheal/bronchial, small 
Primer Sequence Peptide Product bp 
A-I 5 ' -TTGTCTGAGATGGCCTCAGGTGGTAAC-3 '  hBD-1 253 
A-2 5 ' -ATACTTCAAAAGCAATTTTCCTTTAT-3 '  hBD-I 253 
B-I 5 ' -CACTCCAGGCAAGAGCTGATGAGGTTG-3 '  HNPI-3 215 
B-2 5 ' -AATGCCCAGAGTCTTCCCTGGTAGATG-3 '  HNPI-3 215 
C-I 5 ' -TGGTGGCCCTGCAGGCCCAGGCTGAG-3 '  HD5 238 
C-2 5 ' -AGTCTGTAGAGGCGGCCACTGATTTC-3 '  HD5 238 
D-I 5 ' -TCACCATCCTCACTGCTGTTCTCCTC-3 '  HD6 281 
D-2 5 ' -GAATCTGTGGTTAATACCCATGACAG-3 '  HD6 281 
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Fig. 2. Northern blot analysis of hBD-1 expression in various hu- 
man tissues. The filters were loaded with human mRNA from (1) 
heart, (2) brain, (3) placenta, (4) lung, (5) liver, (6) skeletal muscle, 
(7) kidney, (8) pancreas, (9) spleen, (10) thymus, (11) prostate, (12) 
testis, (13) ovary, (14) small intestine, (15) colon, (16) peripheral 
blood leukocyte. Intense hybridization signals can be found in lanes 
7 and 8 (kidney and pancreas). 
airway, and mammary epithelial cells were incubated with 
LPS, IL-6 or phorbol myristate acetate for 4 h and 20 h, 
then their RNA was purified and RT-PCR was performed. 
We also challenged the submaxillary epithelioid carcinoma 
cells with different concentration of LPS (from 50 to 800 
ng/ml), IL-6, PMA, IFN- T, TNF-c~, LPS+IL-6, LPS+PMA, 
LPS+IFN-T, LPS+TNF-cq without inducing hBD-1 message. 
Under none of these experimental conditions did we observe 
any enhanced levels of hBD-1. We concluded, with some dis- 
appointment, that either expression hBD-1 was constitutive in 
hBD-1,25 cycles 
5 9 
HNP 1-3, 25 cycles 
2 6 11 12 13 
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these systems or that it was regulated by stimuli other than 
those reported for bovine TAP. 
Because cattle possess at least 15 different 13-defensins (13 in 
neutrophils [2,3] and one each (TAP and LAP) in tracheal and 
lingual epithelial cells) [6,7], and multiple 13-defensins exist in 
the leukocytes of chickens and turkeys [4,5] we subcloned and 
sequenced 32 different 250 bp RT-PCR products derived from 
human submaxillary gland (8 clones), prostate (8 clones) and 
small intestinal RNA (8 clones) or from the cultured human 
tracheal cells (8 clones). All but two (93.8%) yielded sequences 
identical to hBD-1. One salivary gland clone had a single 
nucleotide difference that would change Val 6 to Ile 6 in the 
mature hBD-1 peptide. A single small intestinal clone also 
had a base pair change that would have changed Gly 25, a 
seventh cysteine residue. We concluded that one or both 
were likely PCR artifacts. 
Overall, these data indicate that hBD-1 is expressed by 
epithelial cells in many human organs. In some tissues, exem- 
plified by the kidney, pancreas, and female reproductive tract, 
hBD-1 mRNA is sufficiently abundant to allow its facile iden- 
tification by Northern blots. Other tissues express hBD-1 in 
relatively smaller amounts, so that more sensitive detection 
techniques uch as RT-PCR are required. 
The current demonstration that the various defensins ex- 
hibit highly tissue-specific expression offers a potential expla- 
nation for why so many different defensin species exist within 
an individual species. Just as the diversification of organisms 
is favored by geographic isolation and environmental selec- 
tion, the differential tissue expression (and consequent spatial 
separation) of defensins uggests that some of their molecular 
diversity is a result of selection pressures exerted by microbial 
pathogens with corresponding tissue tropisms. 
hBD-1,30 cycles 
2 4 8 10 
3 5 7 9 
Fig. 3. Analysis of hBD-1 and HNP1 3 expression in various normal human tissues by RT-PCR. Lane 1, RNA derived from no template; 
lane 2, thymus; lane 3, prostate; lane 4, testis; lane 5, salivary gland; lane 6, skeletal muscle; lane 7, placenta; lane 8, small intestine; lane 9, 
kidney; lane 10, trachea; lane 11, spleen; lane 12, peripheral blood leukocytes; lane 13, bone marrow. Top panels: hBD-1 expression, detected 
as a 253 bp fragment with 25 or 30 cycles of amplification. Middle panels: HNP1 3 expression, detected as a 215 bp fragment, with 25 and 30 
cycles of amplification. Bottom panels: ~-actin expression, detected as a 838 bp fragment, with 25 and 30 cycles of amplification. 
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Fig. 4. RT-PCR analysis of HD5 and HD6 expression. The lane 
number are as defined in Fig. 3. A: HD5 expression was detected 
as a 238 bp fragment. B: HD6 expression was detected as a 281 bp 
fragment. C: ~-actin expression expression was detected as a 838 bp 
fragment. All products were amplified for 35 cycles. 
Overall, the pattern of expression of human [3-defensin 
hBD-1 suggests that its primary role may be to defend epithe- 
lial cells and certain mucosal surfaces from microbial inva- 
sion. In contrast, the presence of ~-defensins HNP I -3  in neu- 
trophils gives these peptides access to all vascularized tissues, 
which permits their participation in systemic host defenses. 
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